Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 12/20 | 0.53 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093296 | 0.91 | UTS2R (0.54) | UTS2RNPY5RALDH1A1L3MBTL1 | |
| SCHEMBL6093163 | 0.90 | UTS2R (0.53) | UTS2RFNTAFNTBALDH1A1L3MBTL1 | |
| SCHEMBL6092652 | 0.87 | UTS2R (0.56) | UTS2R | |
| SCHEMBL6092916 | 0.84 | UTS2R (0.55) | UTS2R | |
| SCHEMBL5463949 | 0.84 | UTS2R (0.64) | UTS2RNPY5RFNTAFNTBALDH1A1 | |
| SCHEMBL6091360 | 0.82 | UTS2R (0.53) | UTS2RL3MBTL1 | |
| SCHEMBL6091146 | 0.81 | UTS2R (0.53) | UTS2RALDH1A1 | |
| SCHEMBL6091406 | 0.81 | UTS2R (0.62) | UTS2RNPY5RFNTAFNTBALDH1A1 | |
| SCHEMBL5458491 | 0.75 | UTS2R (0.62) | UTS2R | |
| SCHEMBL5463931 | 0.73 | UTS2R (0.61) | UTS2RFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006135694-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2006-12-21 | — | — | WO | claimed |
| WO-2006135694-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2006-12-21 | — | — | WO | disclosed |